Skip to main content
Aurinia Pharmaceuticals Inc. logo

Aurinia Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · AUPH ISIN · CA05156V1022 LEI · 5299008YP2BW4570ML28 US Manufacturing
Open in API
Filings indexed 582 across all filing types
Latest filing 2015-05-15 Annual Report
Country CA Canada
Listing US AUPH

About Aurinia Pharmaceuticals Inc.

https://www.auriniapharma.com

Aurinia Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on developing and delivering therapies for patients with severe autoimmune diseases that have high unmet medical needs. The company's principal product is LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN), a serious complication of systemic lupus erythematosus. Aurinia's research and development efforts are centered on immunomodulating therapies for various autoimmune and kidney-related diseases.

Recent filings

Filing Released Lang Actions
AMENDMENT NO. 1 TO FORM 40-F
Annual Report Classification · 100% confidence The document is an Amendment No. 1 to Form 40-F, which is an annual report filed pursuant to the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2014. It includes amended audited consolidated financial statements, management's discussion and analysis (MD&A), and certifications by the CEO and CFO. The document explicitly states it is an amendment to the Annual Report on Form 40-F and contains detailed financial restatements and disclosures related to the annual period. Form 40-F is the Canadian equivalent of the U.S. 10-K annual report. Therefore, this document is an Annual Report amendment filing, which corresponds to the Annual Report (10-K) category in the classification scheme.
2015-05-15 English
AURINIA PHARMACEUTICALS INC. 6-K
Interim / Quarterly Report Classification · 95% confidence The document is a Form 6-K filed by Aurinia Pharmaceuticals Inc., which is a report of a foreign private issuer pursuant to SEC rules. It includes a news release about first quarter 2015 financial results and restatement of 2014 financial statements. Form 6-K filings are typically used by foreign private issuers to report material information that is not required to be filed on Forms 20-F or 40-F. The content indicates it is an interim financial update rather than a full annual report. The document length is short (2117 characters) and it contains a news release about quarterly financial results, which aligns with an Interim / Quarterly Report. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2015-05-15 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Aurinia Pharmaceuticals Inc., dated April 30, 2015. It includes an exhibit index listing a Notice of Annual General Meeting and Management Information Circular, Form of Proxy, Voting Instruction Form, and Request for Annual and Interim Financial Statements and MD&A. The document itself is short (2094 characters) and primarily serves as a report filing with exhibits rather than containing substantive financial data or detailed reports. The presence of proxy and meeting notices suggests it relates to shareholder meeting materials. Given the short length and nature, it is not the full Annual Report or Interim Report but rather a regulatory filing providing meeting-related information and proxy materials. Therefore, the best classification is Regulatory Filings (RNS), as it does not contain the full reports but is a filing of related materials.
2015-04-30 English
AURINIA PHARMACEUTICALS INC. 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Aurinia Pharmaceuticals Inc., which is a report of a foreign private issuer pursuant to SEC rules under the Securities Exchange Act of 1934. Form 6-K filings are typically used by foreign companies to provide current reports and information to the SEC, often including press releases, event notices, or other material information. The document includes a news release about an upcoming meeting and webcast, but does not contain financial statements or detailed financial analysis. The document length is only 2125 characters, indicating it is a brief report rather than a full financial report. Given these factors, this document fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories and includes current reports like Form 6-K.
2015-04-23 English
AURINIA PHARMACEUTICALS INC. 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Aurinia Pharmaceuticals Inc., which is a report of a foreign private issuer pursuant to SEC rules. The text includes a signature by the CFO and an exhibit index referencing a news release about financial results and clinical study initiation. The document length is 2218 characters, which is relatively short and does not contain detailed financial statements or substantive financial data. It primarily serves as a regulatory filing to report information to the SEC and includes a news release as an exhibit. According to the rules, Form 6-K filings are considered Regulatory Filings (RNS) as they are miscellaneous filings that do not fit into other specific categories and often serve as updates or announcements rather than full reports.
2015-03-30 English
FORM 40-F
Annual Report Classification · 100% confidence The document is a Form 40-F filed with the SEC, which is an annual report for a foreign private issuer. It explicitly states it is an "Annual Report pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934" for the fiscal year ended December 31, 2014. It includes references to the Annual Information Form, Audited Consolidated Financial Statements, and Management's Discussion and Analysis, all typical components of an annual report. The document is lengthy (15,000 characters) and contains substantive financial and management information, not just an announcement or certification. Therefore, it fits the definition of an Annual Report (10-K equivalent for foreign issuers).
2015-03-30 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.